カテゴリー： IT/電子, QYResearch, 世界

若年性特発性関節炎治療薬のグローバル市場2023年：経口式、皮下式

◆英語タイトル：Global Juvenile Idiopathic Arthritis Therapeutics Market Research Report 2023

QYResearchが発行した調査報告書（QYR23MA8800）◆商品コード：QYR23MA8800
◆発行会社（リサーチ会社）：QYResearch
◆発行日：2023年3月
◆ページ数：88
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル
◆産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

本調査レポートは世界の若年性特発性関節炎治療薬市場について調査・分析し、世界の若年性特発性関節炎治療薬市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（経口式、皮下式）、用途別セグメント分析（病院、診療所、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Johnson & Johnson Services, Inc.、Novartis International AG、Bristol-Myers Squibb、Zydus Cadila、Takeda Pharmaceutical Company Limited、Genentech, Inc.、Latona Life Sciences.などが含まれています。世界の若年性特発性関節炎治療薬市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、若年性特発性関節炎治療薬市場規模を推定する際に考慮しました。

・若年性特発性関節炎治療薬市場の概要
- 若年性特発性関節炎治療薬のタイプ別セグメント
- 世界の若年性特発性関節炎治療薬市場規模：タイプ別分析（経口式、皮下式）
- 若年性特発性関節炎治療薬の用途別セグメント
- 世界の若年性特発性関節炎治療薬市場規模：用途別分析（病院、診療所、その他）
- 世界の若年性特発性関節炎治療薬市場規模予測（2018年-2029年）

・若年性特発性関節炎治療薬市場の成長トレンド
- 若年性特発性関節炎治療薬の地域別市場規模（2018年-2029年）
- 若年性特発性関節炎治療薬市場ダイナミクス
- 若年性特発性関節炎治療薬の業界動向
- 若年性特発性関節炎治療薬市場の成長ドライバ、課題、阻害要因

・主要企業別競争状況
- 企業別市場シェア
- 世界の主要企業、業界ランキング分析
- 市場への参入、M＆A動向

・タイプ別セグメント：経口式、皮下式
- 世界の若年性特発性関節炎治療薬のタイプ別市場規模（2018年-2023年）
- 世界の若年性特発性関節炎治療薬のタイプ別市場規模（2024年-2029年）

・用途別セグメント：病院、診療所、その他
- 世界の若年性特発性関節炎治療薬の用途別市場規模（2018年-2023年）
- 世界の若年性特発性関節炎治療薬の用途別市場規模（2024年-2029年）

・若年性特発性関節炎治療薬の地域別市場規模
- 北米の若年性特発性関節炎治療薬市場規模（2018年-2029年）
- アメリカの若年性特発性関節炎治療薬市場規模（2018年-2029年）
- ヨーロッパの若年性特発性関節炎治療薬市場規模（2018年-2029年）
- アジア太平洋の若年性特発性関節炎治療薬市場規模（2018年-2029年）
- 中国の若年性特発性関節炎治療薬市場規模（2018年-2029年）
- 日本の若年性特発性関節炎治療薬市場規模（2018年-2029年）
- 韓国の若年性特発性関節炎治療薬市場規模（2018年-2029年）
- インドの若年性特発性関節炎治療薬市場規模（2018年-2029年）
- オーストラリアの若年性特発性関節炎治療薬市場規模（2018年-2029年）
- 中南米の若年性特発性関節炎治療薬市場規模（2018年-2029年）
- 中東・アフリカの若年性特発性関節炎治療薬市場規模（2018年-2029年）

・主要企業のプロファイル：企業情報、事業概要、売上、動向
Johnson & Johnson Services, Inc.、Novartis International AG、Bristol-Myers Squibb、Zydus Cadila、Takeda Pharmaceutical Company Limited、Genentech, Inc.、Latona Life Sciences.

・アナリストの観点/結論

・調査方法とデータソース

Highlights
The global Juvenile Idiopathic Arthritis Therapeutics market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Juvenile Idiopathic Arthritis Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Juvenile Idiopathic Arthritis Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Juvenile Idiopathic Arthritis Therapeutics in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Juvenile Idiopathic Arthritis Therapeutics include Johnson & Johnson Services, Inc., Novartis International AG, Bristol-Myers Squibb, Zydus Cadila, Takeda Pharmaceutical Company Limited, Genentech, Inc. and Latona Life Sciences., etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Juvenile Idiopathic Arthritis Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Juvenile Idiopathic Arthritis Therapeutics.
The Juvenile Idiopathic Arthritis Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Juvenile Idiopathic Arthritis Therapeutics market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Juvenile Idiopathic Arthritis Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Johnson & Johnson Services, Inc.
Novartis International AG
Bristol-Myers Squibb
Zydus Cadila
Takeda Pharmaceutical Company Limited
Genentech, Inc.
Latona Life Sciences.
Segment by Type
Oral
Subcutaneous
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Juvenile Idiopathic Arthritis Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Juvenile Idiopathic Arthritis Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Oral
1.2.3 Subcutaneous
1.3 Market by Application
1.3.1 Global Juvenile Idiopathic Arthritis Therapeutics Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Juvenile Idiopathic Arthritis Therapeutics Market Perspective (2018-2029)
2.2 Juvenile Idiopathic Arthritis Therapeutics Growth Trends by Region
2.2.1 Global Juvenile Idiopathic Arthritis Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Juvenile Idiopathic Arthritis Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Juvenile Idiopathic Arthritis Therapeutics Forecasted Market Size by Region (2024-2029)
2.3 Juvenile Idiopathic Arthritis Therapeutics Market Dynamics
2.3.1 Juvenile Idiopathic Arthritis Therapeutics Industry Trends
2.3.2 Juvenile Idiopathic Arthritis Therapeutics Market Drivers
2.3.3 Juvenile Idiopathic Arthritis Therapeutics Market Challenges
2.3.4 Juvenile Idiopathic Arthritis Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Juvenile Idiopathic Arthritis Therapeutics Players by Revenue
3.1.1 Global Top Juvenile Idiopathic Arthritis Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Juvenile Idiopathic Arthritis Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Juvenile Idiopathic Arthritis Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Juvenile Idiopathic Arthritis Therapeutics Revenue
3.4 Global Juvenile Idiopathic Arthritis Therapeutics Market Concentration Ratio
3.4.1 Global Juvenile Idiopathic Arthritis Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Juvenile Idiopathic Arthritis Therapeutics Revenue in 2022
3.5 Juvenile Idiopathic Arthritis Therapeutics Key Players Head office and Area Served
3.6 Key Players Juvenile Idiopathic Arthritis Therapeutics Product Solution and Service
3.7 Date of Enter into Juvenile Idiopathic Arthritis Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Juvenile Idiopathic Arthritis Therapeutics Breakdown Data by Type
4.1 Global Juvenile Idiopathic Arthritis Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Juvenile Idiopathic Arthritis Therapeutics Forecasted Market Size by Type (2024-2029)
5 Juvenile Idiopathic Arthritis Therapeutics Breakdown Data by Application
5.1 Global Juvenile Idiopathic Arthritis Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Juvenile Idiopathic Arthritis Therapeutics Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Juvenile Idiopathic Arthritis Therapeutics Market Size (2018-2029)
6.2 North America Juvenile Idiopathic Arthritis Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Juvenile Idiopathic Arthritis Therapeutics Market Size by Country (2018-2023)
6.4 North America Juvenile Idiopathic Arthritis Therapeutics Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Juvenile Idiopathic Arthritis Therapeutics Market Size (2018-2029)
7.2 Europe Juvenile Idiopathic Arthritis Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Juvenile Idiopathic Arthritis Therapeutics Market Size by Country (2018-2023)
7.4 Europe Juvenile Idiopathic Arthritis Therapeutics Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Juvenile Idiopathic Arthritis Therapeutics Market Size (2018-2029)
8.2 Asia-Pacific Juvenile Idiopathic Arthritis Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Juvenile Idiopathic Arthritis Therapeutics Market Size by Region (2018-2023)
8.4 Asia-Pacific Juvenile Idiopathic Arthritis Therapeutics Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Juvenile Idiopathic Arthritis Therapeutics Market Size (2018-2029)
9.2 Latin America Juvenile Idiopathic Arthritis Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Juvenile Idiopathic Arthritis Therapeutics Market Size by Country (2018-2023)
9.4 Latin America Juvenile Idiopathic Arthritis Therapeutics Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Juvenile Idiopathic Arthritis Therapeutics Market Size (2018-2029)
10.2 Middle East & Africa Juvenile Idiopathic Arthritis Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Juvenile Idiopathic Arthritis Therapeutics Market Size by Country (2018-2023)
10.4 Middle East & Africa Juvenile Idiopathic Arthritis Therapeutics Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Johnson & Johnson Services, Inc.
11.1.1 Johnson & Johnson Services, Inc. Company Detail
11.1.2 Johnson & Johnson Services, Inc. Business Overview
11.1.3 Johnson & Johnson Services, Inc. Juvenile Idiopathic Arthritis Therapeutics Introduction
11.1.4 Johnson & Johnson Services, Inc. Revenue in Juvenile Idiopathic Arthritis Therapeutics Business (2018-2023)
11.1.5 Johnson & Johnson Services, Inc. Recent Development
11.2 Novartis International AG
11.2.1 Novartis International AG Company Detail
11.2.2 Novartis International AG Business Overview
11.2.3 Novartis International AG Juvenile Idiopathic Arthritis Therapeutics Introduction
11.2.4 Novartis International AG Revenue in Juvenile Idiopathic Arthritis Therapeutics Business (2018-2023)
11.2.5 Novartis International AG Recent Development
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Detail
11.3.2 Bristol-Myers Squibb Business Overview
11.3.3 Bristol-Myers Squibb Juvenile Idiopathic Arthritis Therapeutics Introduction
11.3.4 Bristol-Myers Squibb Revenue in Juvenile Idiopathic Arthritis Therapeutics Business (2018-2023)
11.3.5 Bristol-Myers Squibb Recent Development
11.4 Zydus Cadila
11.4.1 Zydus Cadila Company Detail
11.4.2 Zydus Cadila Business Overview
11.4.3 Zydus Cadila Juvenile Idiopathic Arthritis Therapeutics Introduction
11.4.4 Zydus Cadila Revenue in Juvenile Idiopathic Arthritis Therapeutics Business (2018-2023)
11.4.5 Zydus Cadila Recent Development
11.5 Takeda Pharmaceutical Company Limited
11.5.1 Takeda Pharmaceutical Company Limited Company Detail
11.5.2 Takeda Pharmaceutical Company Limited Business Overview
11.5.3 Takeda Pharmaceutical Company Limited Juvenile Idiopathic Arthritis Therapeutics Introduction
11.5.4 Takeda Pharmaceutical Company Limited Revenue in Juvenile Idiopathic Arthritis Therapeutics Business (2018-2023)
11.5.5 Takeda Pharmaceutical Company Limited Recent Development
11.6 Genentech, Inc.
11.6.1 Genentech, Inc. Company Detail
11.6.2 Genentech, Inc. Business Overview
11.6.3 Genentech, Inc. Juvenile Idiopathic Arthritis Therapeutics Introduction
11.6.4 Genentech, Inc. Revenue in Juvenile Idiopathic Arthritis Therapeutics Business (2018-2023)
11.6.5 Genentech, Inc. Recent Development
11.7 Latona Life Sciences.
11.7.1 Latona Life Sciences. Company Detail
11.7.2 Latona Life Sciences. Business Overview
11.7.3 Latona Life Sciences. Juvenile Idiopathic Arthritis Therapeutics Introduction
11.7.4 Latona Life Sciences. Revenue in Juvenile Idiopathic Arthritis Therapeutics Business (2018-2023)
11.7.5 Latona Life Sciences. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 若年性特発性関節炎治療薬のグローバル市場2023年：経口式、皮下式(Global Juvenile Idiopathic Arthritis Therapeutics Market Research Report 2023)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 医薬品用カンナビス：世界及び中国市場2023
  • 医薬品用カンナビス：世界及び中国市場2023
  • ヤギ関節炎脳炎治療のグローバル市場2023年：非化膿性白質脳脊髄炎（子ヤギ）、非化膿性関節炎・滑膜炎（大人ヤギ）
  • ピーナッツアレルギー治療薬のグローバル市場2023年：エピネフリン注射、抗ヒスタミン薬、経口免疫療法、その他
  • 世界の脾臓チロシンキナーゼ(Syk)阻害剤治療薬市場インサイト及び予測（DNA配列、ポリメラーゼ連鎖反応、質量分析、マイクロアレイ、電気泳動法）